Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine
Open Access
- 12 June 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (10) , 757-758
Abstract
The ChAdOx1 nCoV-19 vaccine (University of Oxford, AstraZeneca and the Serum Institute of India) and the BBV152 vaccine (Bharath Biotech and Indian Council of Medical Research) are the two major vaccines that are used for mass vaccination against COVID-19 in India. 1 The ChAdOx1 nCoV-19 vaccine has been extensively studied and has been authorized for use in several other countries as well. 2 The pooled analysis of four randomized trials has shown that the overall efficacy of the ChAdOx1 nCoV-19 vaccine more than 14 days after the second dose was 66.7% (95% CI 57.4–74.0). Vaccine efficacy against COVID-19 requiring hospital admission from 22 days after the first dose was 100%. 3 Most breakthrough infections occurring after vaccination with ChAdOx1 nCoV-19 were thus mild, requiring no hospital admissions.Keywords
This publication has 2 references indexed in Scilit:
- Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, IndiaDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsThe Lancet, 2021